Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 7:23 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 225 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Deep Venous Thrombosis Clear all

Conditions: Deep Venous Thrombosis
Interventions: Bivalirudin; Drug
Lead sponsor: Children's Hospital Los Angeles; Other
Eligibility: 6 Months to 18 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 6
States / cities: Los Angeles, California • Aurora, Colorado • Columbus, Ohio + 3 more

Conditions: Cerebral Vein Thrombosis, Deep Vein Thrombosis, Gonadal Thrombosis, Hepatic Thrombosis, Malignant Neoplasm, Mesenteric Thrombosis, Metastatic Malignant Neoplasm, Portal Vein Thrombosis, Pulmonary Embolism, Renal Vein Thrombosis, Splenic Thrombosis, Venous Thromboembolism
Interventions: Apixaban, Dalteparin, Questionnaire Administration; Drug · Other
Lead sponsor: Academic and Community Cancer Research United; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 18
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Evanston, Illinois + 15 more

Conditions: Thromboembolism
Interventions: IWPC adapted genotype-guided dosing algorithm for warfarin, Modified IWPC genetic-guided warfarin dosing algorithm, Standard of care treatment; Genetic · Other
Lead sponsor: Intermountain Health Care, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 2,415 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Deep Venous Thrombosis, Pulmonary Embolism
Interventions: Not listed
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999 – 2003
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Deep Venous Thrombosis
Interventions: Cirvo Compression device; Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Stanford, California

Conditions: Deep Vein Thrombosis, Pulmonary Embolism, Venous Thromboembolism
Interventions: Standard heparin dose, Real time heparin dose adjustment; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Venous Thrombosis
Interventions: PD 0348292, Enoxaparin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 1,225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 58
States / cities: Birmingham, Alabama • Little Rock, Arkansas • North Little Rock, Arkansas + 29 more

Conditions: Deep Venous Thrombosis
Interventions: Not listed
Lead sponsor: Sir Mortimer B. Davis - Jewish General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 803 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 3
States / cities: Detroit, Michigan • Durham, North Carolina • Oklahoma City, Oklahoma

Conditions: Venous Thromboembolism, Pulmonary Embolism, Deep Vein Thrombosis, Cancer, Surgery
Interventions: Exposure to clinical decision support system and education; Behavioral
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Artificial Heart Valve
Interventions: Genotype-guided dose determination, Non-genotype guided warfarin dosing; Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Atrial Fibrillation, Deep Venous Thrombosis, Heart Valve Replacement, Pulmonary Embolism
Interventions: Coumadin; Drug
Lead sponsor: Agency for Healthcare Research and Quality (AHRQ); Federal
Eligibility: 40 Years and older
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 2
States / cities: Madison, Wisconsin • Marshfield, Wisconsin

Conditions: Venous Thromboembolism, Deep Venous Thrombosis, Post-Thrombotic Syndrome
Interventions: ClotTriever System, Commercially available/market approved anticoagulation medication including but not limited to: Heparin Sodium, Coumadin, Rivaroxaban, Apixaban, etc.; Device · Drug
Lead sponsor: Inari Medical; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 48
States / cities: Scottsdale, Arizona • Tucson, Arizona • Orange, California + 43 more

Conditions: Deep Venous Thromboses
Interventions: STAT Venous Duplex, Routine Venous Duplex; Diagnostic Test
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Deep Vein Thrombosis, Pulmonary Embolism
Interventions: Discontinue anticoagulant therapy (Negative d-dimer), Continue on anticoagulant therapy (positive d-dimer); Other
Lead sponsor: McMaster University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 410 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 7
States / cities: Washington D.C., District of Columbia • Iowa City, Iowa • Boston, Massachusetts + 3 more

Conditions: Acute Deep Vein Thrombosis
Interventions: Thrombolysis in combination with endhole aspiration; Device
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Deep Venous Thrombosis
Interventions: Low-Molecular-Weight Heparin; Drug
Lead sponsor: University of Tennessee; Other
Eligibility: 18 Years to 85 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Chattanooga, Tennessee

Conditions: Deep Vein Thrombosis
Interventions: Apixaban, Placebo; Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 3
States / cities: Rochester, Minnesota • Eau Claire, Wisconsin • La Crosse, Wisconsin

Conditions: Pregnancy, Deep Vein Thrombosis
Interventions: LEFt clinical decision rule; Other
Lead sponsor: Ottawa Hospital Research Institute; Other
Eligibility: 16 Years and older · Female only
Enrollment: 366 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: Murray, Utah

Conditions: Deep Vein Thrombosis, Pulmonary Embolism
Interventions: Fondaparinux; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Thrombosis, Deep Vein, Iliofemoral; Thrombosis
Interventions: Perivascular dexamethasone, Perivascular sham; Combination Product
Lead sponsor: Mercator MedSystems, Inc.; Industry
Eligibility: 18 Years to 89 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 20
States / cities: Scottsdale, Arizona • Orange, California • Darien, Connecticut + 16 more

Conditions: Deep Vein Thrombosis, Fibrillation, Atrial, Venous Thromboembolism, Pulmonary Embolism
Interventions: Odiparcil, Warfarin, Coumadin; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 35 Years and older
Enrollment: 961 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 46
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 37 more

Conditions: Deep Vein Thrombosis, DVT
Interventions: Not listed
Lead sponsor: Emergency Medicine Physicians, Nevada; Other
Eligibility: 18 Years and older
Enrollment: 288 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Deep Vein Thrombosis, Venous Thrombosis, Postphlebitic Syndrome, Venous Thromboembolism, Post Thrombotic Syndrome
Interventions: Recombinant tissue plasminogen activator (rt-PA); Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 16 Years to 75 Years
Enrollment: 692 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 56
States / cities: Glendale, Arizona • Orange, California • Stanford, California + 48 more

Conditions: Critical Illness, Deep Venous Thrombosis
Interventions: LMWH (Fragmin, dalteparin), Unfractionated Heparin; Drug
Lead sponsor: McMaster University; Other
Eligibility: 18 Years and older
Enrollment: 3,659 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 4
States / cities: Rochester, Minnesota • St Louis, Missouri • Providence, Rhode Island + 1 more

Search by objective public record fields.

The UNBLOCK Study: Utilization of Bivalirudin On Clots in Kids

Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism

Applying Pharmacogenetic Algorithms to Individualize Dosing of Warfarin

Risk Factors for Venous Thromboembolism

Radial, Sequential Compression Device Deep Venous Thrombosis Detection Study

Evaluation of Anti-Xa Levels in Surgery Patients Receiving Weight-based Heparin

Evaluation of PD 0348292 for Preventing Blood Clots in the Lungs or Deep Leg Veins of Patients After Knee Surgery

Biomarker Sub Study of the Compression Stockings to Prevent the Post-Thrombotic Syndrome (SOX) Trial

Intervention to Improve Utilization of Extended Venous Thromboembolism Prophylaxis After Cancer Surgery

Genotype-Guided Warfarin Therapy Trial

Modeling Genotype and Other Factors to Enhance the Safety of Coumadin Prescribing

DEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis

DVT Evaluation Using POCUS for Diagnosis and Treatment

D-dimer to Select Patients With First Unprovoked Venous Thromboembolism Who Can Have Anticoagulants Stopped at 3 Months

Safety and Efficacy of Thrombolysis in Combination With Endhole Aspiration in the Treatment of Acute DVT

Low-Molecular-Weight Heparin (LMWH) for Deep Venous Thrombosis (DVT) Prophylaxis

Calf Deep Vein Thrombosis Treatment Trial

Safely Ruling Out Deep Vein Thrombosis in Pregnancy With the LEFt Clinical Decision Rule and D-Dimer

Fondaparinux as Monotherapy for DVT and/or Pulmonary Embolism

Perivenous Dexamethasone Therapy: Examining Reduction of Inflammation After Thrombus Removal to Yield Benefit in Acute Femoropopliteal DVT

Odiparcil For The Prevention Of Venous Thromboembolism

DVT Ultrasound in the Emergency Department

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT)